I thought Sonya Colberg and Adam F.'s bashes were hilarious before data release. Absolutely zero analysis on the science SMH. What a bunch of hacks reading tea leaves and agreeing with market sentiment.
The data release should be very close now. Database lock, QA check and stat analysis shouldn't be long. I liked that Culley released a pic on twitter as a public disclosure. This phase 3 will be as good as its phase 2.
Brendan relax! When I was on the CPXX board at less than 1.3, there were 3 longs and 1 short (multiple ids around 5-7). No one cared. I even sent a message to Adam. F via mailbag and he flat out said prediction: fail. Sonya C. bashed it too saying it's a scam. When positive results are released you will see a flux of people come in and you and I will be the original longs. MSTX is similar to CPXX in that their phase 3 should be viewed as an exploratory phase 2 that ran out of money. They still achieved a finding of significance for a particular sub-group. Have hope because the science is there. The science supports the mechanism. However, Mr. Market or funds will not want to touch this because it has been diluted and went through a phase 3 fail etc. It's better for most to invest after the data release.
Extension studies are always a good sign. It's costly...there needs to be a degree of confidence on the part of the company and investigators though all parties are blinded. This means the effect of the drug must be obvious. Like others have mentioned...safety and whether repeats would be of concern are important for the filing.
This is not an oncology company so no...F-R rule doesn't apply here. However, it shares similarities in that VOC drugs are limited so the pricing of drugs is higher.
Blinded before the extension is what I was getting at. There is obviously some confidence here as to whether or not there is a clinical effect for patients to continue to open label. Investigators are recommending their patients to participate.
Are you for real? You're complaining about a move from .27 to .41c in a month? This thing will continue to go up until phase 3 release. It doesn't even look like end of June but rather mid June latest. And if it goes up it wiill go up to 500 M market cap after the release.
For sure, volume is not normal. This is too crazy. I think data release this week or next week. Someone is probably working on a PR or internal communication leak.
If you work for Cohen and you are posting like this then you are at risk of market manipulation. It's obvious you are bashing to accumulate. Since why bother shorting a penny stock and lose everything. Just move on.
Thanks for letting us know that you don't know how to invest. We'll just have to ignore your advice on this one as well because you don't have any real arguments as to why this trial won't succeed.
The data is poor. Botched lab analysis shows less than 1% improvement. No proof that the 1% improvement translates to a clinical effect. The walk tests couldn't show a difference between historical controls either. The drug is as good as someone not taking it..that's why the FDA won't approve.